LABU

Is LABU a buy right now?

LABU is 3x daily exposure to the S&P biotech index — an equal-weighted basket of biotech stocks that moves on FDA decisions, clinical trial data, and M&A speculation. Unlike market-cap-weighted indexes, XBI gives small-cap biotechs equal influence, which means bigger swings and faster trends. At 3x leverage, timing isn't optional — it's the entire strategy.

The honest answer to "should I buy LABU?" is never a hot take — it's a trend question. When XBI is in a confirmed uptrend, 3x daily leverage compounds in your favor. When it's choppy or falling, the same math works against you fast. Our current read is in the ticket above.

How the LevSig system trades LABU

Our proprietary signal engine runs a multi-indicator trend confirmation system on XBI every trading day after the close. Here's how it works at a high level:

• Entry: Multiple momentum and trend indicators must align before a LONG signal fires. No single indicator can trigger a trade alone.
• Exit: An adaptive ATR-based trailing stop that ratchets up with the trend and never loosens, calibrated to each underlying's volatility.
• Re-entry: Momentum-based re-entry logic to get back into trends that resume after a stop-out.
• Everything else: Flat, in cash. No shorting, no averaging down, no opinions.

The full methodology, backtest results, and live track record are documented on our performance page.

Why you can't just buy and hold LABU

LABU rebalances to 3x exposure every single day. In a steady trend that's rocket fuel. In a sideways market, the daily reset systematically bleeds value — a phenomenon called volatility decay. XBI can finish a quarter flat while LABU finishes it down double digits. Our Learn section covers the math in plain English.

Frequently asked

Compare